Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Cefalexin 500mg capsules
0501021L0AAABAB
|
Cefalexin | Cefalexin | Infections | 74,710 |
|
Cefalexin 250mg capsules
0501021L0AAAAAA
|
Cefalexin | Cefalexin | Infections | 51,960 |
|
Cefalexin 500mg tablets
0501021L0AAAHAH
|
Cefalexin | Cefalexin | Infections | 26,522 |
|
Cefalexin 250mg tablets
0501021L0AAAGAG
|
Cefalexin | Cefalexin | Infections | 25,657 |
|
Cefalexin 125mg/5ml oral suspension
0501021L0AAACAC
|
Cefalexin | Cefalexin | Infections | 11,017 |
|
Cefalexin 250mg/5ml oral suspension
0501021L0AAADAD
|
Cefalexin | Cefalexin | Infections | 10,499 |
|
Cefalexin 250mg/5ml oral suspension sugar free
0501021L0AAAPAP
|
Cefalexin | Cefalexin | Infections | 5,311 |
|
Cefalexin 125mg/5ml oral suspension sugar free
0501021L0AAANAN
|
Cefalexin | Cefalexin | Infections | 4,994 |
|
Keflex 250mg capsules
0501021L0BCAAAA
|
Keflex | Cefalexin | Infections | 5 |
|
Keflex 500mg tablets
0501021L0BCADAH
|
Keflex | Cefalexin | Infections | 4 |
|
Keflex 250mg tablets
0501021L0BCACAG
|
Keflex | Cefalexin | Infections | 3 |
|
Cefalexin 500mg/5ml oral suspension
0501021L0AAAEAE
|
Cefalexin | Cefalexin | Infections | No data available |
|
Ceporex 125mg/5ml syrup
0501021L0BBAHAC
|
Ceporex | Cefalexin | Infections | No data available |
|
Ceporex 250mg capsules
0501021L0BBAAAA
|
Ceporex | Cefalexin | Infections | No data available |
|
Ceporex 250mg tablets
0501021L0BBACAG
|
Ceporex | Cefalexin | Infections | No data available |
|
Ceporex 250mg/5ml syrup
0501021L0BBAIAD
|
Ceporex | Cefalexin | Infections | No data available |
|
Ceporex 500mg capsules
0501021L0BBABAB
|
Ceporex | Cefalexin | Infections | No data available |
|
Ceporex 500mg tablets
0501021L0BBADAH
|
Ceporex | Cefalexin | Infections | No data available |
|
Ceporex 500mg/5ml syrup
0501021L0BBAJAE
|
Ceporex | Cefalexin | Infections | No data available |
|
Keflex 125mg/5ml oral suspension
0501021L0BCAEAC
|
Keflex | Cefalexin | Infections | No data available |
|
Keflex 250mg/5ml oral suspension
0501021L0BCAFAD
|
Keflex | Cefalexin | Infections | No data available |
|
Keflex 500mg capsules
0501021L0BCABAB
|
Keflex | Cefalexin | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.